Skip to main content

The European malaria vaccine development association

Objective

The goal of the European Malaria Vaccine Development Association (EMVDA) integrated project is to systematically develop and test prototype malaria vaccines by comparative and continuous evaluation of candidate vaccines and move these as quickly as possible to clinical studies. Our emphasis will be on 'downstream' vaccine pre- clinical development and clinical trials. A product development management structure will be set up that will be responsible for the technical and regulatory management of the transition of candidate vaccines between the production groups and clinical testing groups. Exploiting the capabilities of 3 SMEs, 9 European malaria vaccine research centres, the European Malaria Vaccine Initiative (EMVI) and the African Malaria Network (AMANET), we aim to establish a scientific and technological structure supported by effective management. Stringent go/no-go criteria will be used to assess and compare competing antigens and delivery systems to focus resources on to the most credible vaccine candidates. Our internal Training Programme, which will be integrated with that of the existing Framework Programme 6 funded malaria-oriented Network of Excellence (BIOMALPAR) will promote interdisciplinary collaboration and support for our African partners, AMANET, particularly with their training programmes for young African scientists. Working closely with our African partners, standard operating procedures governing all in vitro and in vivo immuno-assays used by the consortium during vaccine development will be developed and distributed. The EMVDA project brings together Europe's leading malaria vaccine researchers and pan-Union initiatives in an unprecedented collaboration with vaccine SMEs and the African Malaria Network to drive the production and clinical development of an effective vaccine to protect those vulnerable to this disease and thus aid human development.'

Call for proposal

FP6-2005-LIFESCIHEALTH-6
See other projects for this call

Funding Scheme

IP - Integrated Project

Coordinator

EUROPEAN VACCINE INITIATIVE
Address
Im Neuenheimer Feld 307
Heidelberg
Germany

Participants (15)

CRUCELL HOLLAND B.V.
Netherlands
Address
Archimedesweg 4
Leiden
PEVION BIOTECH LTD.
Switzerland
Address
Rehhagstrasse 79
Berne
CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
United Kingdom
Address
University Offices, Weillington Square
Oxford
FOUNDATION BIOMEDICAL PRIMATE RESEARCH CENTRE
Netherlands
Address
Lange Kleiweg 139
3306 Rijswijk
THE UNIVERSITY OF EDINBURGH
United Kingdom
Address
Old College, South Bridge
Edinburgh
STICHTING KATHOLIEKE UNIVERSITEIT
Netherlands
Address
Geert Grooteplein-noord 9
9101 Nijmegen
MEDICAL RESEARCH COUNCIL
United Kingdom
Address
20 Park Crescent
London
AFRICAN MALARIA NETWORK TRUST
Tanzania
Address
Ali Hassan Mwinyi Road
33207 Dar Es Salaam
SWISS TROPICAL INSTITUTE
Switzerland
Address
Socinstr.57
Basel
STOCKHOLM UNIVERSITY
Sweden
Address
Universitetsvägen 10
Stockholm
HOSPICES CANTONAUX CHUV
Switzerland
Address
Rue Du Bugnon 21
Lausanne
EBERHARD-KARLS UNIVERSITAET TUEBINGEN
Germany
Address
Wilhelmstrasse 7
Tübingen
ETNA BIOTECH S.R.L.
Italy
Address
Piazza Stesicoro 59
Catania
RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG
Germany
Address
Seminarstrasse 2
Heidelberg
STATENS SERUM INSTITUT
Denmark
Address
Artillerivej 5
Copenhagen S